

Accuracy of routine biomarkers and blood leucocytes count to assist diagnosis of COVID-19-associated pneumonia in adult patients visiting the emergency department

Cécile Maincent

Princess Grace hospital center

Frédéric Berthier

Centre Hospitalier Princesse Grace

Ryan Lukas Farhad

Centre Hospitalier Princesse Grace

Cristel Fissore-Magdelein

Centre Hospitalier Princesse Grace

Claire Claire Dittlot

Centre Hospitalier Princesse Grace

Nathalie Beau

Centre Hospitalier Princesse Grace

Jérémy Lépine

Centre Hospitalier Princesse Grace

Marjorie Lorillou

Centre Hospitalier Princesse Grace

Matthieu Dietz

Centre Hospitalier Princesse Grace

Mathieu Liberatore

Centre Hospitalier Princesse Grace

Atul Pathak

Centre Hospitalier Princesse Grace

Marc Marc Faraggi

Centre Hospitalier Princesse Grace

Sylvie Chaillou-Orpitz

Centre Hospitalier Princesse Grace

Olivia Keita-Perse

Centre Hospitalier Princesse Grace

Gilles Chironi

Centre Hospitalier Princesse Grace

Christophe Perrin

Centre Hospitalier Princesse Grace


Yann-Erick Claessens (✉ ye.claessens@gmail.com)

Centre Hospitalier Princesse Grace

Original research

Keywords: COVID, pneumonia, diagnosis, leucocytes count, basophilic count, eosinophilic count, fibrinogen, routine analysis, emergency medicine

DOI: <https://doi.org/10.21203/rs.3.rs-34817/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background To investigate whether routine biomarkers and blood leucocytes count could assist diagnosis of COVID-19-associated pneumonia in adult patients visiting the emergency department (ED).

Methods This monocentre retrospective study enrolled 254 patients with nasopharyngeal RT-PCR for SARS-COV-2, routine biomarkers (D-dimers, fibrinogen, C-reactive protein, procalcitonin, NTpro-BNP, cTnT-hs) and blood cell counts. Sensitivity and specificity were evaluated. An adjudication committee classified diagnostic probability as certain, probable, unlikely, and excluded, based on all available data, then distributed in 2 categories: high (certain and probable) and low probability (unlikely and excluded).

Results Between 25th of February and 15th of April, 2020, 254 of 388 patients could be analyzed. The adjudication committee classified 46 patients as definite, 18 as probable, 64 as unlikely, and 126 as excluded, corresponding to 64 high and 190 low probability. High and low probability patients differed for fibrinogen ($P < 0.0005$) and white blood cell counts, notably leucocytes ($P = 0.0015$), neutrophilic ($P = 0.0036$), lymphocytes ($P = 0.0057$), eosinophilic ($P = 0.027$), and basophilic ($P < 0.001$) counts. In a multivariate analysis, basophilic count $< 25/\mu\text{L}$ (OR 3.048 [95%CI; 1.34-6.919]), neutrophilic count $< 4000 /\mu\text{L}$ (OR 5.525 [95%CI; 2.20-13.855], and fibrinogen $> 3\text{g/L}$ (OR 6355 [95%CI; 2.01-20.079] were independently associated with the diagnosis. Negative predictive values were 0.98 and 0.93 combining fibrinogen ($< 3\text{g/L}$) and eosinophilic count ($< 80/\mu\text{L}$), and fibrinogen and basophilic count ($< 25/\mu\text{L}$), respectively.

Conclusion Changes in fibrinogen and white blood cells, notably basophilic count, showed interesting performance for the diagnosis COVID-19 associated pneumonia. Combining fibrinogen with either eosinophilic or basophilic count was helpful to exclude the diagnosis.

Introduction

In December 2019, the onset of an outbreak related to SARS-CoV-2 occurred, an unknown coronavirus detected in January 2020 [1,2] and responsible for a disorder termed COVID-19. Since then, COVID-19 has spread worldwide and is responsible for an unprecedented pandemic with major threat on global health, and social and economic stability [3].

COVID-19 has a large spectrum of symptoms. Most patients seem to experience mild or moderate flu-like disorder with cough, fever, and shortness of breath [4]. More severe presentations may occur and some patients develop an acute pneumonia that can lead to an acute respiratory distress syndrome (ARDS) [5,6]. Clinical signs and symptoms are poorly specific, and an early diagnosis is crucial to isolate the patients and treat them in dedicated units. Positive diagnosis mostly relies on detection of the virus by RT-PCR in the upper respiratory tract [7,8] and suggestive images on chest CT-scan [9]. However, RT-PCR may be falsely negative in the early phase and CT abnormalities might be equivocal or lack specificity. Moreover RT-PCR results and CT-scan may be delayed and/or unavailable. As shortage of resources may occur during such a healthcare crisis [10], special attention should be paid to usual laboratory analysis in the management of patients suspected of COVID-19 infection during the phase of uncertain diagnosis. Several changes in biomarkers have been reported in COVID-19 infection: changes in leucocytes counts, notably lymphocytic and eosinophilic counts, elevation of D-dimers and cardiac biomarkers (since coronavirus may have cardiac and endothelial tropism and induce thrombosis and cardiovascular abnormalities). Professional and scientific societies and healthcare organizations have endorsed the use of routine biomarkers and blood cell count to assist physicians at bedside [11-14]. Whereas numerous studies reported the prognostic value of such laboratory data, a limited number were dedicated to diagnosis.

Therefore, while facing the outbreak, evaluating the role of routine biomarkers and leucocytes to guide diagnosis toward COVID-19 or alternative diagnoses is mandatory to better select patients since the Emergency Departments (ED) and fix hospital organization [15].

Methods

We designed a single center, retrospective, observational study conducted from February 25th. 2020 to April 15th 2020 in the Emergency Department (ED) of Princess Grace Hospital, a general hospital in Monaco. The study was monitored by the research

department of our Hospital. No funding was obtained for this study. The ethical board held for the study approved the protocol and waived the need of a written informed consent for inclusion. The protocol was registered in the clinicaltrials.gov website under the MONACOVID-Biomarkers acronym (NCT04401241). The National laws for Ethics did not require informed consent. The study complied with STARD recommendations [16].

Objectives

The primary objective was to assess sensitivity of routine biomarkers and blood cell count for diagnosis of COVID-19-associated pneumonia in low and high probability groups for COVID-19-associated pneumonia classified by an adjudication committee.

Secondary objectives were i) to compare values of routine biomarkers and blood cell count amongst the four different categories of level of certainty; ii) to assess performance of combined routine biomarkers and blood cell count for diagnosis of COVID-19-associated pneumonia; iii) to assess whether usual biomarkers and blood cell count were associated with diagnosis of COVID-19-associated pneumonia using sensitivity analyses in predefined subgroups chosen a priori; 1) when comparing definite versus excluded patients; 2) when comparing high vs. low probability patients, excluding bacterial infection (respiratory and extra-respiratory) in the low probability COVID-19-associated pneumonia group; 3) when comparing definite versus excluded probability patients, excluding bacterial infections (respiratory and extra-respiratory) in excluded patients.

Adjudication committee

An adjudication committee consisting of two independent senior experts in infectious diseases and pneumology retrospectively assigned the probability of COVID-19-associated pneumonia diagnosis using the 4-level Likert scale, based on data collected from baseline on standardized case report forms, results of SARS-Cov-2 specific RT-PCR, of low dose chest CT-Scan, and full access to all available data including patients' discharge summary. To note, the adjudication committee was blinded for classification by an independent senior radiologist of low dose chest CT-scan. A Likert scale allowed distribution of patients in four categories: 1) absence of COVID-19-associated pneumonia referred as excluded; 2) unlikely COVID-19-associated pneumonia; 3) probable COVID-19-associated pneumonia; and 4) definite COVID-19-associated pneumonia. After adjudication committee classification, patients were distributed in two groups: low probability of COVID-19-associated pneumonia (excluded and unlikely) and high probability of COVID-19-associated pneumonia (probable and definite).

For this study, the gold standard was the diagnosis assessed by the adjudication committee. Alternative diagnoses were established for low probability COVID-19-associated pneumonia and classified as i) non-COVID viral respiratory tract infection; ii) non-COVID bacterial respiratory tract infection; iii) respiratory tract disorder at the exclusion of infectious diseases; iv) extra-pulmonary infectious diseases; and v) miscellaneous.

Study population

For the study purpose and to ensure quality of the final adjudication committee diagnosis, we selected consecutive adults (18 years of age and above) visiting the COVID-19 dedicated ED who presented with clinically suspected COVID-19-associated pneumonia and had SARS-Cov-2 RT-PCR. Clinically suspected COVID-19-associated pneumonia was based on physician's judgment and fulfilling the following criteria: new onset of symptoms concordant with viral infection (at least one of the following: sweat; chills; myalgia; temperature ≥ 38 °C or < 36 °C or perception of fever; loss of smell and/or taste; diarrhea) and symptoms of an acute lower respiratory tract disorder (at least one of the following: cough; sputum production; respiratory rate ≥ 20 per minute; dyspnea; chest pain; altered breathing sounds at auscultation). We selected patients whose presentation required a blood sample for global and severity assessment.

Patient management and usual biomarkers and blood cell count

Patients' management in the COVID-19-dedicated ED was based on local protocolized practices based on a collegial multidisciplinary decision if they presented with suspected COVID-19-associated pneumonia. Recorded baseline data consisted of demographic data (age; gender), medical history of coexisting conditions; treatments; symptoms; clinical findings and predetermined laboratory tests including: SARS-Cov-2 specific RT-PCR obtained on nasopharyngeal swab; low-dose chest CT-scan; standard blood analysis (complete blood count; hemostasis; metabolic panel; creatinine; blood urea nitrogen; liver enzymes); D-

dimers (Vidas. Biomérieux); Procalcitonin (PCT); C-reactive protein (CRP); high sensitive cardiac troponin T; NT-pro-brain natriuretic peptide (NT-proBNP, all on Cobas, Roche diagnostics).

Microbiological samples

Nasopharyngeal swabs were collected at admission and placed in a Middle Virocult MWE (Sigma®) transport medium. Samples were kept at room temperature and sent to the laboratory immediately after collection. For the presence of SARS-COV-2, swabs were sent to french referent centres for virological analysis (Nice, Marseille, Paris). Routine microbiological examinations were performed at the discretion of the emergency physicians and included: presence of *influenza A* and *B* viruses and *respiratory syncytial virus (RSV) A* and *B* on nasopharyngeal swabs; blood culture; urine antigens for *Streptococcus pneumoniae* and *Legionella pneumophila type I*; serodiagnosis of *Mycoplasma pneumoniae*. These results were available to the adjudication committee.

Low dose chest CT-scan data and COVID-19-associated pneumonia diagnosis classification

Multidetector low dose thoracic CT-scan was performed for each individual patient and interpretation was recorded using a standardized report form. The low dose chest CT-scans were independently reviewed by a senior radiologist, blinded from other data, and classified for probability of COVID-19-associated pneumonia as 1) excluded; 2) unlikely; 3) probable; and 4) definite.

Statistical analysis

Baseline and follow-up characteristics were described by means and standard deviations (SD) or by median and interquartile range (IQR) for continuous variables with normal or with skewed distribution, respectively, and by percentages for categorical variables. Chi-square or Fisher exact tests were performed when appropriate for qualitative variables. The Student or Mann–Whitney tests were used to compare baseline characteristics and study outcomes between study groups for continuous variables with skewed distributions.

The distribution of values for usual biomarkers and blood cell count were determined in the different populations of patients using boxplots. The performances of current laboratory data in predicting definite COVID-19-associated pneumonia were evaluated by sensitivity analysis (definite vs excluded COVID-19-associated pneumonia). CRP was evaluated at several cut-off points of 20 mg/L, 50 mg/L, and 100 mg/L, values used in previous studies [17]. Several cut-off points for PCT were chosen at the level of 0.10 µg/L [17] and at the two levels for suspected bacterial infection 0.25 µg/L and 0.50 µg/L. Cut-offs for cTnT-hs were 14 ng/L and 50 ng/L, as stated by the manufacturer. Cut-offs for D-dimers test were 500 µg/ml and age-adjusted threshold [18]. Sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs), and likelihood ratio were calculated. Receiver operating characteristic (ROC) curves were drawn, area under the curve AUC was computed and optimal cut-off was identified by the maximization of the Youden's index, comparing laboratory results values in patients with excluded COVID-19-associated pneumonia and definite COVID-19-associated pneumonia. From these optimal cut-offs for laboratory results, sensitivity analyses were performed combining cut-offs.

A multivariate logistic regression model was built to identify factors associated with having high probability of COVID-19-associated pneumonia as compared to having an excluded COVID-19-associated pneumonia diagnosis. All variables with a p value of < 0.15 in the bivariate analysis were entered into a multivariate logistic regression with a backward stepwise approach; the discrimination was evaluated by the C-index and its 95 % confidence interval (95 % CI) and the calibration was evaluated by the Hosmer Lemeshow goodness-of-fit test.

All tests were two-sided, and p-values below 0.05 were considered to denote statistical significance. All statistical analyses were performed using SAS 9.1. (SAS Institute, Cary, NC, USA).

Results

Characteristics of the population

During the study period, 388 patients with suspected COVID-19-associated pneumonia and nasopharyngeal swab for SARS-Cov-2 RT-PCR visited the dedicated ED. One hundred and thirty four patients could not be included since routine biological results were missing for 128 and 6 were under 18 years of age (Figure 1). Two hundred and fifty four adults patients with available routine laboratory results were selected for analysis (Table 1); 102 patients (39.7%) were 65 years of age or older. The number of patients suffering from significant underlying disorders was 103 (41.5 %), including 43 (17.3 %) with pulmonary disorders. Cough (n=163, 64.1%), dyspnea (n = 109, 42.8%), and perception of fever (n = 103, 40.9%) were the most frequent symptoms. Pulmonary auscultation detected unilateral or bilateral crackles in 65 (32.5%), and 33 (13.3%) patients had anosmia / ageusia. SARS-CoV-2 RT-PCR was positive in 42 (16.5%). Blood cultures were positive in 8 patients: *Escherichia coli* in 3, *Staphylococcus* in 2 (*S. capitis*, n = 1; *S. hominis*, n = 1); *Enterococcus faecalis* (n = 2); *Streptococcus intermedius* (n = 1).

Low dose chest CT scan results

Pulmonary infiltrates were described in 123 (62.8 %) out of 196 patients with low dose chest CT-scan. Ground glass opacities were reported in 68 patients, peripheral distribution in 66, linear condensation in 48, and crazy paving in 8. Most patients with CT-scan (81.3%) had an extent of parenchymal abnormalities below 25%. After being reviewed by an independent senior radiologist, low dose chest CT-scan was classified as definite in 40 (33.3%) and excluded in 64 (53.3%).

Adjudication committee classification

Classification by the adjudication committee for COVID-19 associated pneumonia was definite in 46 (17.4 %), probable in 18 (6.8 %), unlikely in 64 (25.2 %), and excluded in 126 (49.6 %). This corresponded to 64 high probability and 190 low probability COVID-19-associated pneumonia. Among alternative diagnoses for low probability patients included, we observed 36 noninfectious pulmonary disorders (including 3 pulmonary embolisms), 26 viral lower respiratory tract infections (LRTI), 9 bacterial LRTI, 26 extra-respiratory bacterial infections.

Performance of routine biomarkers and blood leucocytes count for diagnosis of COVID-19-associated pneumonia

Among patients with high probability for COVID-19 associated pneumonia, PCT concentration was low, eosinophilic and lymphocytic counts were below normal range and levels of fibrinogen, D-dimers and CRP were increased. Lymphopenia ($\leq 1000 / \mu\text{L}$) was observed in 26.0%, eosinopenia ($\leq 10 / \mu\text{L}$) in 28.0%, high fibrinogen concentrations ($>3.42 \text{ g/L}$) in 55.3%. When comparing high and low probability patients, a significant decrease was observed in nearly each leucocytes neutrophilic, lymphocytic, basophilic and eosinophilic counts; fibrinogen measurement was significantly elevated in high probability patients (Table 2). Distribution of these 6 variables amongst the 4-level Likert scale categories are reported in Figure 2. Global performance of these parameters remained modest and none had an AUC above 0.80. Other parameters did not differ between the high and low probability groups.

Amongst all parameters, a drop in basophilic count showed valuable characteristics to ascertain diagnosis (Table 3). Indeed, positive likelihood ratios were 6.94 and 5.96 at a cut-off of 0 and $10 / \mu\text{L}$, respectively. Performance for positive diagnosis was lower with other leucocytes counts (Table 4). To rule out the diagnosis, high neutrophilic and lymphocytes counts were of interest. Negative likelihood ratio was 0.46 for both neutrophilic count above $7500 / \mu\text{l}$ and lymphocytes count above $2500 / \mu\text{l}$. Results for other parameters are detailed in Supplementary data. When comparing patients with definite or excluded COVID-19 associated pneumonia, similar results were observed (Table 3). A multivariate analysis showed interesting individual characteristics of basophilic counts, neutrophilic counts and fibrinogen measurement at the Youden's index value to help positive diagnosis of COVID-19 associated pneumonia (Table 5).

Performance of routine biomarkers and blood leucocytes count for diagnosis of COVID-19-associated pneumonia, excluding bacterial infection

To better assess sensitivity, we compared patients with high and low probability when bacterial infections were removed from the study population (Table 3). Removing bacterial infection decreased the performance of total leucocytes count (AUC 0.687 [0.607-0.767] vs. 0.666 [0.583-0.749]) and neutrophilic count (AUC 0.651 [0.569-0.733] vs. 0.616 [0.531-0.701]). Conversely, removing

bacterial infection did not alter characteristics of eosinophilic count (AUC 0.653 [0.571-0.735] vs. 0.683 [0.601-0.765]), basophilic count (AUC 0.714 [0.635-0.793] vs. 0.726 [0.647-0.805]), lymphocytes count (AUC 0.637 [0.554-0.720] vs. 0.669 [0.586-0.752]), and fibrinogen (AUC 0.671 [0.583-0.759] vs 0.71 [0.623-0.797]). Similar effects were observed when bacterial infection were removed from comparison of definite and excluded COVID-19 associated pneumonia (Table 3).

Performance of combined parameters for diagnosis of COVID-19-associated pneumonia, excluding bacterial infection

We assessed the accuracy of combining fibrinogen and different leucocytes counts at the Youden's index value. We observed that fibrinogen combined with eosinophilic count had interesting characteristics to exclude diagnosis of COVID-19-associated pneumonia, with NPV 0.98 [95% CI, 0.868; 0.9994](Se 98%, NPV 98%, LR- 0.007), and outperformed combination of fibrinogen and basophilic count, whose NPV was 0.93 (Se 93%, LR- 0.22). Combination was poorly specific for both fibrinogen and eosinophilic count (Sp 26%, PPV 0.32, LR+ 1.33), and fibrinogen and basophilic count (Sp 33%, PPV 0.33, LR+ 1.39).

Discussion

Here we report the accuracy of leucocytes counts and routine biomarkers to assist diagnosis of COVID-19 associated pneumonia in patients visiting the emergency department with pneumonia-like symptoms. The major strength of the present study is the control group to whom COVID-19 patients were compared. Our results highlighted the ability of basophilic count to exclude or confirm the diagnosis. We also observed that neutrophilic, lymphocytes and eosinophilic counts, and fibrinogen had interesting characteristics. Combining fibrinogen with either eosinophilic or basophilic count was helpful to exclude the diagnosis of COVID-19 associated pneumonia. Cardiac biomarkers and D-dimers test were of limited values at the emergency department.

Several scientific societies and healthcare organisms have supported the use of common biological results to manage COVID-19 patients [8, 11–14]. The value of leucocytes counts to assist diagnosis of COVID-19 has been advocated since the beginning of the outbreak. Drop in lymphocytes and eosinophilic counts has been proposed to guide diagnosis process. Lymphopenia has been reported as the most frequent abnormality [19, 20], observed in up to 82%. The decrease in eosinophilic count has also been underlined [21]. A study comparing patients with COVID-19 (n = 52) and LRTI (n = 53) reported lower eosinophils count in COVID-19 (0.02 / μ L vs. 0.05 / μ L, P value 0.004), and frequent eosinopenia (78.8% vs. 35.8%, P value < 0.001) [22]. In this study, leukocyte counts had no diagnostic value. Combining eosinopenia to clinical signs improved sensitivity and specificity (78.8% and 64.2%, respectively), as did lymphopenia (48.1% and 52.8%). While our results are in accordance with these results, we showed that leucocytes could also be of interest. We also reported that low basophilic count frequently occurred and had good diagnostic performance. This abnormality has not been reported so far. So far, we have been unable to provide specific explanation. We believe that a drop in basophilic count should be investigated in other series of viral infection, including COVID-19. Combining eosinophilic count (≤ 80 / μ l) and fibrinogen (≥ 3 g/L) could help excluding diagnosis of COVID-19 in patients with a flu-like pneumonia. Indeed, we reported the good predictive values of fibrinogen measurements. Fibrinogen is associated with worse prognosis of COVID patients, as described for D-dimers test [23]. Activation of coagulation and major risk of venous thromboembolism are described in COVID patients, in relation with the so-called cytokines storm [24]. Therefore, increase in coagulation markers is foreseen. Interestingly acute fibrinous and organizing pneumonia (AFOP)-like pneumonia are described in SARS-Cov-2 infected patients [25]. Therefore it cannot be excluded that D-dimers increase could partly be related to the presence of fibrinogen in the lung compartment.

In COVID-19 patients, PCT is mostly below 0.25 μ g/L [12, 19]. In case of a superinfection, levels of PCT are usually measured above 0.5 μ g/L and significantly elevated as compared to patients with a pure COVID pneumonia (OR 4.76 [95% CI, 2.74–8.29]) [26]. Although we reported no difference in PCT concentration between different levels of certainty, the low concentrations advocate for a potent use for stewardship. In our population, PCT measurements significantly differed between patients with a definite diagnosis of COVID-associated pneumonia and those with a bacterial infection (0.08 [0.05–0.12] vs. 0.17 [0.06–1.32], P value 0.0222, data not shown). To note, this did not apply to CRP (P value 0.62, data not shown). Despite results from previous studies [27], we have been unable to detect any difference between groups for cardiac biomarkers [27].

We acknowledge that our results have limitations. For this study, we used retrospective data because of the urge of the sanitary situation and the relative resolution of the pandemic. This obviously leads to some bias. First, this method elicits missing data among laboratory measurements. Second, 128 adult patients analyzed for the presence of SARS-COV-2 using RT-PCR could not be

included because no routine laboratory analysis was ordered. These patients significantly differ from the population analyzed in this study since none was admitted. Therefore we did not capture all the population with flu-like syndrome but focused on patients with potential pneumonia. This explains that blood analysis was not ordered for some patients. Finally, we analyzed data available for attending physicians that obviously used them at bedside. Additionally, the adjudication committee may have utilized these laboratory results to classify patients for level of certainty. We previously reported such a methodology to classify community-acquired pneumonia [28]. Indeed, it was asked to adjudication committees to comment their decision for classification. It appears that classification mostly relied on RT-PCR and CT-scan for positive diagnosis; the committees seldom quoted the use of routine biological parameters to assist their decision.

Conclusion

Guidelines have endorsed the use of routine laboratory analysis to help physicians making a diagnosis of COVID-associated pneumonia. Our results underscored the significance of blood cell counts analysis, the notable value of fibrinogen, and advocate for the use of combined eosinophilic or basophilic count and fibrinogen measurement to exclude diagnosis. COVID-19 may become endemic, senior UN health official Mike Ryan declared on Wednesday, 13rd of May, 2020. This announcement strengthens the need for physicians to get reliable results for data available in daily practice, and underlines the scope of the present study.

Declarations

Ethical Approval and Consent to participate

The ethical board held for the study approved the protocol and waived the need of a written informed consent for inclusion. The National laws for Ethics did not require informed consent.

Consent for publication

All authors have critically read and commented on draft versions of the report, and approved the final version.

Availability of supporting data

Extensive access to data is available on request.

Competing interests

The authors declare no competing interests.

Funding

Not applicable.

Authors' contributions

YEC and FB developed the study design. CFM was responsible for laboratory data collection. YEC and FB had full access to the data and take responsibility for the accuracy of the data analysis. FB and performed the statistical analysis. All authors assisted

with data interpretation. YEC performed the literature search and wrote the first draft of the paper. All authors have critically read and commented on draft versions of the report, and approved the final version.

Acknowledgments

We thank all patients for participating in this study, and members of the MONACOVID Study Group. Department of Anaesthesiology and Intensive Care Medicine: M Bourregba; JP Guerin; G Rousseau; I Rouquette. Department of Biology: C Fissore-Magdelein; S Gabriel-Solean. Department of Biostatistics: F Berthier. Department of Cardiologie: G Chironi; V Dupasquier; A Pathak. Department of Clinical Research: C Dugourd; M Nicolai; N Rijo. Department of Emergency Medicine: N Beau; YE Claessens; X Magdelein. Department of Gastrotrenterology: F Olyve. Department of Infectious diseases: S Chaillou-Orpitz; RL Farhad; O Keita-Perse. Department of Nuclear Medicine: M Dietz; M Faraggi. Department of Pneumology: J Lépine; M Lorillou; C Maincent; C Perrin. Department of Radiology: S Bertrand; P Brunner; C Dittlot; F Fuerxer; M Liberatore.

References

1. Stop the Wuhan virus. *Nature*. 2020;577(7791):450.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.
3. Chen Z, Cao C, Yang G. Coordinated multi-sectoral efforts needed to address the COVID-19 pandemic: lessons from China and the United States. *Glob Health Res Policy* 2020;5:22.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497-506.
5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395(10223):507-13.
6. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020;323(11):1061-9.
7. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020. *BMJ* 2020;369:m1443.
8. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 25 January 2020. Published January 25, 2020. Accessed March 20, 2020. <https://apps.who.int/iris/handle/10665/330854>
9. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). *Radiology* 2020;295(1):202-7.
10. Rowan NJ, Laffey JG. Challenges and solutions for addressing critical shortage of supply chain for personal and protective equipment (PPE) arising from Coronavirus disease (COVID19) pandemic - Case study from the Republic of Ireland. *Sci Total Environ* 2020;725:138532.
11. Handbook of COVID-19 Prevention and Treatment. Chinese guidelines, 18/03/2020. alnap.org/help-library/handbook-of-covid-19-prevention-and-treatment.
12. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020;382:1708-20.
13. Qu JM, Wang C, Cao B; Chinese Thoracic Society Chinese Association of Chest Physician. Guidance for the management of adult patients with coronavirus disease 2019. *Chin Med J* 2020 doi: 10.1097/CM9.0000000000000899.
14. Interim Clinical Guidance for Management of Patients, CDC guidelines, 30/03/2020. www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
15. Her M. Repurposing and reshaping of hospitals during the COVID-19 outbreak in South Korea. *One Health* 2020. doi: 10.1016/j.onehlt.2020.100137.

16. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC; Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003;326(7379):41-4.
17. Le Bel J, Hausfater P, Chenevier-Gobeaux C, Blanc FX, Benjoar M, Ficko C, et al. Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having a systematic thoracic CT scan. *Crit Care* 2015;19:366.
18. Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. *JAMA* 2014;311(16):1117-24.
19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 2020. DOI:[https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
20. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* ciaa248 <https://doi.org/10.1093/cid/ciaa248>
21. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020. doi: 10.1111/all.14238.
22. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID 2019 infection. *Clin Chem Lab Med* 2020. pii: [/j/cclm.ahead-of-print/cclm-2020-0198/cclm-2020-0198.xml](https://doi.org/10.1515/cclm-2020-0198). doi: 10.1515/cclm-2020-0198.
23. Li Q, Ding X, Xia G, Geng Z, Chen F, Wang L, Wang Z. A simple laboratory parameter facilitates early identification of COVID-19 patients. doi: <https://doi.org/10.1101/2020.02.13.20022830>.
24. Vaninov N. In the eye of the COVID-19 cytokine storm. *Nat Rev Immunol*. 2020;20(5):277.
25. Copin M, Parmentier E, Duburcq T, Poissy J, Mathieu D, Lille COVID-19 ICU and Anatomopathology Group. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. *Intensive Care Med*. 2020. doi:10.1007/s00134-020-06057-8
26. Lippi G. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. *Clin Chim Acta* 2020;505:190-1.
27. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020. doi: 10.1001/jamacardio.2020.1017.
28. Claessens YE, Debray MP, Tubach F, Brun AL, Rammaert B, Hausfater P, et al. Early chest CT-scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. *Am J Respir Crit Care Med* 2015;192(8):974-82.

Table Legends

Table 1. Characteristics of the study population.

Table 2. Comparison of leucocytes counts, C-reactive protein, procalcitonin, fibrinogen, D-dimers, N-terminal pro-brain natriuretic peptide, and high sensitive cardiac troponin T in patients with high or low probability for COVID-19 associated pneumonia.

Table 3. Comparison of leucocytes counts, C-reactive protein, procalcitonin, fibrinogen, D-dimers, N-terminal pro-brain natriuretic peptide, and high sensitive cardiac troponin T in patients with high or low probability for COVID-19 associated pneumonia and excluded bacterial infections, and in patients with definite or excluded COVID-19 associated pneumonia, with or without bacterial infections.

Table 4. Performance of fibrinogen, lymphocytes, neutrophil, eosinophil, and basophil polymorphonuclear leucocytes, according to different cut-offs in the patients with high or low probability for COVID-19 associated pneumonia.

Table 5. Multivariate analysis of the characteristics of high and low probability COVID-19 associated pneumonia.

Supplementary data. Performance of CRP, PCT, D-dimers and cTnT-hs, according to different cut-offs in the patients with high or low probability for COVID-19 associated pneumonia.

Tables

Table 1.

General characteristics	
Age	
Mean age (years)	57.8 ± 21.0
≥ 65 years	102 (39.7)
Sex	
Female	126 (49.0)
Male	131 (51.0)
Nursing home resident	8 (4.0)
Comorbidities	
At least 1 comorbidity	103 (41.5)
Chronic respiratory disease	43 (17.3)
Congestive heart failure	33 (13.3)
Kidney disease	13 (5.3)
Neoplasia	6 (2.4)
Liver disease	4 (1.6)
History of stroke	10 (4.0)
Weight	
Community-acquired pneumonia characteristics at inclusion	
Antibiotics before ED visit	44 (17.2)
Antiviral therapy before ED visit	6 (2.3)
Symptoms duration before visiting ED (days)	5.9 ± 6.6
Signs and symptoms in the ED	
Cough	163 (64.1)
Chest pain	48 (19.0)
Expectoration	17 (6.7)
Dyspnea	109 (42.8)
Chills	89 (35.6)
Headaches	60 (23.9)
Myalgia	56 (22.4)
Crackles	53 (20.8)
Perception of fever	103 (40.9)
Anosmia / ageusia	33 (13.3)
Diarrhea	61 (24.4)
Temperature	37.4 (0.9)
Respiratory rate	19.1 (4.8)
SatO ₂	96.6 (2.6)
Heart rate	88.2 (17.1)
Confusion	9 (3.5)
Pleural effusion	32 (14.8)
Microbiological data	
Positive PCR SARS-Cov-2	42 (16.5)
Positive PCR Influenza A	4 (2.3)
Positive PCR Influenza B	6 (3.4)
Positive pneumococcal antigenuria	3 (2)
Positive blood culture	8 (3.5)
General laboratory data	
Glycaemia (mmol/L)	6.4 ± 1.7
Urea (mmol/L)	6.1 ± 3.9
pH	7.44 ± 0.07
PaO ₂ (mmHg)	74.2 ± 23.3
Haematocrit	0.39 ± 0.05
Outcome	
Discharge	126 (49.6)

Admission General ward	119 (46.9)
Admission ICU	8 (3.2)
28-day mortality	1 (0.3)
Low dose CT-scan probability for COVID-19 associated pneumonia (n=193)	
Definite	40 (33.3)
Probable	5 (4.2)
Unlikely	11 (9.2)
Excluded	64 (53.3)

Table 2.

	N	Total population	High probability	Low probability	AUC	P value
White blood cell counts						
Leucocytes (10 ³ /mm ³)	255	7800 [5950-10210]	6455 [4440-8170]	8200 [6760-10775]	0.687 [0.607-0.767]	0.0015
Neutrophils (10 ³ /mm ³)	254	5349.5 [3770-7844]	4116 [3240-6290]	5538.5 [4073-8447]	0.651 [0.569-0.733]	0.0036
Eosinophils (10 ³ /mm ³)	254	62 [16-154]	31 [8-72]	78.5 [22-174.5]	0.653 [0.571-0.735]	0.027
Basophils (10 ³ /mm ³)	254	32.5 [20-52]	20 [9-39]	38.5 [24.5-54.5]	0.714 [0.635-0.793]	< 0.0001
Monocytes (10 ³ /mm ³)	254	580 [413-829]	537 [364-702]	606 [431.5-840.5]	0.579 [0.495-0.663]	0.3386
Lymphocytes (10 ³ /mm ³)	254	1470 [998-2146]	1057 [792-1692]	1570.5 [1091.5-2198]	0.637 [0.554-0.720]	0.0057
Biomarkers						
C-reactive protein (mg/L)	253	6.9 [1.4-41.8]	17.6 [4.1-51.4]	4.2 [1-38.9]	0.620 [0.537-0.703]	0.4614
Procalcitonin (µg/L)	198	0.06 [0.04-0.12]	0.07 [0.05-0.12]	0.05 [0.04-0.12]	0.573 [0.480-0.666]	0.253
D-dimers (µg/L)	171	636 [283-1333]	886 [439-1475]	518 [251-1333]	0.613 [0.515-0.711]	0.4468
Fibrinogen (g/L)	208	3.6 [2.83-4.36]	4.04 [3.3-4.75]	3.42 [2.65-4.19]	0.671 [0.583-0.759]	0.0005
NTproBNP (pg/mL)	209	83.28 [24.79-491]	72.1 [26.34-210.75]	93.45 [24.17-581.3]	0.573 [0.480-0.666]	0.3052
cTroponin T-hs (ng/L)	213	0.007 [0.003-0.015]	0.007 [0.005-0.013]	0.006 [0.003-0.016]	0.515 [0.427-0.603]	0.1745

Table 3.

	High vs. Low probability. excluded bacterial infections			Definite vs. Excluded			Definite vs. Excluded. excluded bacterial infections		
	N	AUC	P value	N	AUC	P value	N	AUC	P value
Leucocytes	219	0.666 [0.583- 0.749]	0.0143	170	0.735 [0.644- 0.826]	0.0004	137	0.706 [0.609- 0.803]	0.0057
Neutrophils	218	0.616 [0.531- 0.701]	0.043	169	0.695 [0.599- 0.791]	0.0012	136	0.646 [0.544- 0.748]	0.0249
Eosinophils	218	0.683 [0.601- 0.765]	0.0085	169	0.727 [0.634- 0.820]	0.001	136	0.775 [0.685- 0.865]	0.0002
Basophils	218	0.726 [0.647- 0.805]	<0.0001	169	0.800 [0.716- 0.884]	< 0.0001	136	0.816 [0.733- 0.899]	<0.0001
Monocytes	218	0.579 [0.493- 0.665]	0.3389	169	0.603 [0.503- 0.703]	0.4171	136	0.599 [0.495- 0.703]	0.4302
Lymphocytes	218	0.669 [0.586- 0.752]	0.001	169	0.685 [0.583- 0.749]	0.001	136	0.734 [0.639- 0.829]	0.0001
C-reactive protein	217	0.668 [0.585- 0.751]	0.1532	168	0.654 [0.556- 0.752]	0.49	135	0.742 [0.648- 0.836]	0.1992
Procalcitonin	174	0.626 [0.532- 0.720]	0.6306	137	0.563 [0.454- 0.672]	0.2553	115	0.635 [0.524- 0.746]	0.6279
D-dimers	150	0.658 [0.560- 0.756]	0.1458	125	0.647 [0.533- 0.761]	0.2659	105	0.711 [0.599- 0.823]	0.0649
Fibrinogen	180	0.710 [0.623- 0.797]	<0.0001	146	0.716 [0.616- 0.816]	0.0008	120	0.778 [0.683- 0.873]	0.0002
NTproBNP	183	0.544 [0.452- 0.636]	0.7039	142	0.615 [0.507- 0.723]	0.2794	118	0.568 [0.455- 0.681]	0.5015
cTroponin T-hs	189	0.541 [0.450- 0.632]	0.283	145	0.512 [0.405- 0.619]	0.1769	122	0.548 [0.437- 0.659]	0.3195

Table 4.

Parameters Cut-off	Se	Sp	PPV	NPV	LR+	LR-
Neutrophils cut-off						
≤ 2500 /μL	17.46	95.21	55.00	77.49	3.65	0.87
≤ 4000 /μL (Youden)	47.62	76.06	40.00	81.25	1.99	0.69
≤ 5000 /μL	60.32	59.04	33.04	81.62	1.47	0.67
≤ 7500 /μL	85.71	30.85	29.35	86.57	1.24	0.46
≤ 10000 / μL	93.65	14.89	26.94	87.50	1.10	0.43
Lymphocytes cut-off						
≤ 750 /μL	19.3	87.77	34.29	76.39	1.58	0.92
≤ 1000 /μL (Youden)	42.86	79.26	40.91	80.54	2.07	0.72
≤ 1500 /μL	68.25	53.19	32.82	83.33	1.46	0.60
≤ 2000 /μL	77.78	31.38	27.53	80.82	1.13	0.71
≤ 2500 /μL	93.65	13.83	26.70	89.67	1.09	0.46
Eosinophils cut-off						
0	22.22	89.36	41.18	77.42	2.09	0.87
< 15 /μL	42.86	81.91	44.26	81.05	2.37	0.70
< 50 /μL	60.32	61.7	34.55	82.27	1.57	0.64
< 80 /μL (Youden)	79.37	48.94	34.25	87.62	1.55	0.42
< 120 /μL	82.54	36.17	30.23	86.08	1.29	0.48
≤ 250 /μL	92.06	13.3	26.24	83.33	1.06	0.60
Basophils cut-off						
0	11.11	98.4	70.00	76.76	6.94	0.90
≤ 10 /μL	25.4	95.74	66.67	79.30	5.96	0.78
≤ 25 /μL (Youden)	61.9	75	45.35	85.45	2.48	0.51
≤ 50 /μL	84.13	31.91	29.28	85.71	1.24	0.50
≤ 75 /μL	95.24	9.04	25.97	85.00	1.05	0.53
≤ 100 /μL	98.41	2.66	25.31	83.33	1.01	0.60
Fibrinogen cut-off						
> 2.5g/L	94.55	19.87	30.06	90.91	1.18	0.27
> 3.0 g/L (Youden)	89.09	39.74	35.00	90.91	1.48	0.27
> 3.5 g/L	69.09	53.64	35.19	82.65	1.49	0.58
> 4.0 g/L	52.73	72.19	40.85	80.74	1.90	0.65
> 5.0 g/L	20	90.07	42.31	75.56	2.01	0.89

Youden corresponds to Youden's index, the optimized cut-off for sensitivity and specificity. Abbreviations. Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR-: negative likelihood ratio; Neutrophils: Neutrophil Polymorphonuclear Leucocytes; Eosinophils: Eosinophil Polymorphonuclear Leucocytes; Basophils: Basophil Polymorphonuclear Leucocytes.

Table 5.

Parameters	OR	[95% CI]
Basophils < 25 / μ L	3.048	[1.34-6.919]
Eosinophils <80 / μ L	2.16	[0.85-5.43]
Neutrophils <4000 / μ L	5.525	[2.20-13.855]
Fibrinogen <3 g/L	6.355	[2.01-20.079]
Lymphocytes < 1500 / μ L	0.84	[0.34-2.048]
CRP < 20mg/L	1.159	[0.44-3.007]
Gender	1.12	[0.51-2.444]
Age	0.998	[0.97-1.019]

Abbreviations. OR : Odds ratio; 95% CI : 95% confidence interval; Neutrophils: Neutrophil Polymorphonuclear Leucocytes; Eosinophils: Eosinophil Polymorphonuclear Leucocytes; Basophils: Basophil Polymorphonuclear Leucocytes; CRP : C-reactive protein.

Supplementary data.

Parameters' Cut-off	Se	Sp	PPV	NPV	LR+	LR-
CRP cut-off						
> 20 mg/L (Youden)	49,21	66,84	33,33	79,62	1,48	0,76
> 50 mg/L	26,98	80,75	32,08	76,65	1,40	0,90
> 100 mg/L	11,11	88,77	25,00	74,77	0,99	1,00
PCT cut-off						
> 0.10 µg/L	58.33	30.39	23.08	67.39	0.84	1.37
> 0.25 µg/L	94.44	16.83	28.81	89.47	1.14	0.33
> 0.50 µg/L	97.22	16.83	29.41	94.44	1.17	0.17
D-dimers cut-off						
> 500 µg/L	77.72	48.94	33.33	86.79	1.52	0.46
age-adjusted	70.97	53.19	33.33	84.75	1.52	0.55
cTnT-hs cut-off						
14 µg/L	25	67.89	20.45	73.27	0.78	1.10
50 µg/L	2.78	91.74	10.00	74.07	0.34	1.06

Youden corresponds to the optimized cut-off for sensitivity and specificity. Abbreviations. Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR-: negative likelihood ratio; CRP: C-reactive protein; PCT: procalcitonin; age-adjusted: age-adjusted cut-off over 50 years (age x10); cTnT-hs: high sensitive cardiac troponin T.

Figures




Figure 1

Chart flow.




Figure 2

Distribution (boxplot) of leucocytes count, neutrophil count, eosinophil count, basophil count and fibrinogen measurement each level of diagnosis certainty of COVID-19-associated pneumonia according to diagnosis certainty classification (adjudication committee).